# A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

> **NCT06761417** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 49 (estimated)

## Conditions studied

- Solid Tumors
- Children
- Adolescents

## Interventions

- **DRUG:** Mitoxantrone liposome
- **DRUG:** Capecitabine
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06761417
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761417, "A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06761417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*